153 related articles for article (PubMed ID: 15618757)
1. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature.
Kato M; Chiba K; Hisaka A; Ishigami M; Kayama M; Mizuno N; Nagata Y; Takakuwa S; Tsukamoto Y; Ueda K; Kusuhara H; Ito K; Sugiyama Y
Drug Metab Pharmacokinet; 2003; 18(6):365-72. PubMed ID: 15618757
[TBL] [Abstract][Full Text] [Related]
2. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
3. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.
Tachibana T; Kato M; Sugiyama Y
Pharm Res; 2012 Mar; 29(3):651-68. PubMed ID: 21913031
[TBL] [Abstract][Full Text] [Related]
4. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
5. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
6. A comparison of pharmacokinetics between humans and monkeys.
Akabane T; Tabata K; Kadono K; Sakuda S; Terashita S; Teramura T
Drug Metab Dispos; 2010 Feb; 38(2):308-16. PubMed ID: 19910513
[TBL] [Abstract][Full Text] [Related]
7. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
8. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
9. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.
Takahashi M; Washio T; Suzuki N; Igeta K; Yamashita S
J Pharm Sci; 2009 Nov; 98(11):4343-53. PubMed ID: 19230019
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction.
Shen DD; Kunze KL; Thummel KE
Adv Drug Deliv Rev; 1997 Sep; 27(2-3):99-127. PubMed ID: 10837554
[TBL] [Abstract][Full Text] [Related]
11. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor.
Kadono K; Akabane T; Tabata K; Gato K; Terashita S; Teramura T
Drug Metab Dispos; 2010 Jul; 38(7):1230-7. PubMed ID: 20354105
[TBL] [Abstract][Full Text] [Related]
12. Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats.
Wang X; Zheng M; Liu J; Huang Z; Bai Y; Ren Z; Wang Z; Tian Y; Qiao Z; Liu W; Feng F
J Ethnopharmacol; 2017 Sep; 209():175-183. PubMed ID: 28755970
[TBL] [Abstract][Full Text] [Related]
13. The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.
Takano J; Maeda K; Bolger MB; Sugiyama Y
Drug Metab Dispos; 2016 Nov; 44(11):1808-1818. PubMed ID: 27538919
[TBL] [Abstract][Full Text] [Related]
14. Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats.
Aiba T; Takehara Y; Okuno M; Hashimoto Y
Pharm Res; 2003 May; 20(5):745-8. PubMed ID: 12751629
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study.
Watanabe T; Maeda K; Nakai C; Sugiyama Y
J Pharm Sci; 2013 Sep; 102(9):3196-204. PubMed ID: 23754337
[TBL] [Abstract][Full Text] [Related]
16. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel substrates for human cytochrome P450 2J2.
Lee CA; Neul D; Clouser-Roche A; Dalvie D; Wester MR; Jiang Y; Jones JP; Freiwald S; Zientek M; Totah RA
Drug Metab Dispos; 2010 Feb; 38(2):347-56. PubMed ID: 19923256
[TBL] [Abstract][Full Text] [Related]
18. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
19. Impact of P-Glycoprotein on Intestinal Absorption of an Inhibitor of Apoptosis Protein Antagonist in Rats: Mechanisms of Nonlinear Pharmacokinetics and Food Effects.
Yamamoto S; Kosugi Y; Hirabayashi H; Moriwaki T
Pharm Res; 2018 Aug; 35(10):190. PubMed ID: 30105478
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
